|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.48 USD | -0.38% |
|
-0.47% | -28.95% |
| 07-30 | Daxor Launches Blood Testing Lab in Eastern Kansis | MT |
| 07-30 | Daxor Corporation Initiates Outpatient Blood Volume Analysis Program in Kansas | CI |
| Market Cap | 61.07M 52.89M 49.3M 45.35M 85.61M 5.81B 86.57M 579M 227M 2.91B 229M 224M 9.62B | P/E 2026 * |
-49.9x | P/E 2027 * | -349x |
|---|---|---|---|---|---|
| Enterprise Value | 61.07M 52.89M 49.3M 45.35M 85.61M 5.81B 86.57M 579M 227M 2.91B 229M 224M 9.62B | EV / Sales 2026 * |
5.13x | EV / Sales 2027 * | 2.94x |
| Free-Float |
46.74% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Daxor Corporation
| 1 week | -0.47% | ||
| Current month | -0.19% | ||
| 1 month | +0.96% | ||
| 3 months | -3.44% | ||
| 6 months | -14.52% | ||
| Current year | -28.95% |
| 1 week | 10.11 | 11 | |
| 1 month | 10.05 | 11.97 | |
| 3 years | 6.55 | 14.76 | |
| 5 years | 6.55 | 14.76 | |
| 10 years | 3.4 | 24.08 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 31/12/2012 | |
Robert Michel
DFI | Director of Finance/CFO | 69 | 27/09/2018 |
John Jefferies
CTO | Chief Tech/Sci/R&D Officer | - | 04/06/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
James Lombard
BRD | Director/Board Member | 91 | 31/12/1988 |
| Chairman | 56 | 13/02/2017 | |
| Director/Board Member | 61 | 13/02/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.38% | -0.47% | +5.12% | +9.36% | 61.07M | ||
| +4.08% | +5.10% | +24.01% | +112.92% | 15.24B | ||
| +4.55% | +9.06% | +57.43% | +150.99% | 12.78B | ||
| -0.03% | +6.13% | -2.52% | +33.02% | 9.36B | ||
| +4.17% | +6.44% | +36.68% | +132.77% | 7.86B | ||
| -0.80% | +0.63% | -17.12% | -17.29% | 7.39B | ||
| -0.23% | +1.17% | +14.94% | +42.70% | 6.38B | ||
| -0.13% | -0.49% | +9.29% | +23.95% | 4.76B | ||
| -0.65% | -2.64% | +9.42% | +6.37% | 4.03B | ||
| -0.65% | +6.16% | - | - | 3.81B | ||
| Average | +1.15% | +3.34% | +15.25% | +54.98% | 7.96B | |
| Weighted average by Cap. | +1.95% | +4.38% | +20.86% | +77.91% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 11.9M 10.31M 9.61M 8.84M 16.68M 1.13B 16.87M 113M 44.31M 566M 44.69M 43.71M 1.88B | 20.8M 18.01M 16.79M 15.45M 29.16M 1.98B 29.48M 197M 77.45M 990M 78.12M 76.4M 3.28B |
| Net income | -1.2M -1.04M -969K -891K -1.68M -114M -1.7M -11.38M -4.47M -57.09M -4.51M -4.41M -189M | -200K -173K -161K -149K -280K -19.02M -284K -1.9M -745K -9.52M -751K -735K -31.51M |
| Net Debt | - | - |
Employees
-
Sector
Closed End Funds
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/08/26 | US$10.48 | -0.38% | 315 |
| 04/08/26 | US$10.52 | -3.04% | 3,119 |
| 03/08/26 | US$10.85 | +3.33% | 689 |
| 31/07/26 | US$10.50 | - | 870 |
| 30/07/26 | US$0.000000 | -100.00% | 115 |
Sell
Buy

Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.48USD
Average target price
22.50USD
Spread / Average Target
+114.69%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DXR Stock
- DXR Stock
Select your edition
All financial news and data tailored to specific country editions

















